All In Biotech

Drug Trial Radar · NCT01422915

Sorbent Therapy of the Cutaneous Porphyrias

Last checked: Nov 20, 2026Latest source record: Apr 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4

Actual

Start

May 2011

Primary completion

Mar 2012

Study completion Mar 2012

Sponsor

Lead sponsor
Brigham and Women's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 25, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 22 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The investigators demonstrated that cholestyramine is an effective binding agent in vitro for porphyrins. A few isolated case reports of treatment of individuals with a cutaneous porphyria suggest that cholestyramine and colestipol effectively remove porphyrins. Hypothesis: orally administered colestipol will effectively reduce sun sensitivity and lower erythrocyte porphyrin concentrations in subjects with erythropoietic protoporphyria (EPP).

Conditions

  • Erythropoietic Protoporphyria

Interventions

  • ColestipolDrug

    2 grams morning and bedtime for 90 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Photosensitivity, Assessed by Measuring the Number of Minutes of Sun ToleranceTime frame: At 60 days of treatment
  2. Protoporphyrin Concentration in BloodTime frame: Samples collected while on treatment (range 93-208 treatment days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Brigham & Women's Hospital

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.